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ABSTRACT
Natural killer (NK) cell-mediated cytotoxicity can control leukemia relapse while protecting patients from graft-
versus-host disease (GVHD) after allogeneic stem cell transplant. Cord blood (CB) is rich inNK cell progenitors
with similar properties of proliferation and cytotoxicity as adult blood NK cells. Hence, it is attractive to expand
and potentially utilize these cells for adoptive immunotherapy. In this study, CB mononuclear cells were CD3-
depleted by immunomagnetic microbead selection to remove T cells. This CD3dep CB-MNC fraction was then
plated for ex vivo expansion, with or without a feeder layer of irradiated umbilical cord mesenchymal stem cells
(UC-MSC), with or without cytokines that have been shown to be critical for NK expansion: IL-2, IL-15, IL-3,
and FLT-3L. At an average of 2 weeks of culture, there was significantly higher expansion (64.7 ± 8.4-fold) of
CD561/CD32 NK cells in the presence of the UC-MSC feeder layer and cytokines compared to controls (no
increase with feeder layer only and 6.4 ± 1.5-fold increase with cytokines only, P\ .05). Contact betweenCD3dep
CB-MNC cells andUC-MSC augmentedNKexpansion. The combination of all 4 cytokines was superior to IL-2
alone or 2 cytokines combinations: mean 64.7 ± 8.4-fold expansion with 4 cytokines combination versus IL-2
alone, IL-2 1 FLT-3L, IL-2 1 IL-15 or IL-2 1 IL-3 (12.2 ± 2.0, 14.4 ± 2.4, 10.4 ± 4.1, 25.2 ± 8.1 respectively).
We also observed that only fresh CD3dep CB-MNCpreparations could be expanded reliably, whereas frozen and
thawed CD3dep CB-MNC cells did not expand consistently (mean fold increase 6.5 ± 3.2). Cytotoxicity of ex-
panded NK cells was compared with NK cells from fresh and overnight IL-2 activated CD3dep CB-MNC.
Whereas fresh cells displayed no discernible killing, strong cytotoxicity against K562, Raji, REH, and SUP-
B15 cells lines was noted after overnight activation in IL-2. Cytotoxicity of expanded NK cells against Raji,
REH, and SUP-B15 was lower, which, however, correlated with a predominant expansion of CD561/CD162
cells known to have less cytolytic activity than CD561/CD161. To test the transfection efficiency in NK cells,
fresh or expanded CD3dep CB-MNC cells were electroporated with either DNA or mRNA constructs for
GFP. DNA had a low transfection efficiency (\10%), whereas the one for mRNA reached 52%, but at the
cost of significant cell death. Our results suggest that CB NK cell progenitors can be expanded to obtain large
numbers by using an irradiated feeder of UC-MSC. They maintain an elevated cytotoxic profile, and may be
genetically manipulated—all characteristics that make them suitable for cellular therapies.
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Natural killer (NK) cells represent a subpopulation
of lymphocytes that expressCD56andCD16 (FcgRIII)
but lack lineage specific antigens for T cells (CD3), B
cells (CD19), or monocytes (CD14) [1-4]. They medi-
ate antibody-dependent cellular cytotoxicity as well as‘‘spontaneous’’ killing of infected or transformed cells
through release of perforin and granzyme from cyto-
toxic granules. NK cells are also able of secreting
immunoregulatory cytokines, particularly interferon
(IFN)-g, TNF-a, and GM-CSF. Recent preclinical
and clinical data suggest thatNKcellsmayplay apivotal1031
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transplantation by reducing leukemia relapse and
protecting recipients from graft-versus-host disease
(GVHD) [5,6]. Further studies in patients with ad-
vanced AML have suggested that infusion of CD3-
depleted MHC 1-haplotype mismatched mononuclear
cells enriched for NK cells, can induce remissions in
about 20% of patients with chemotherapy resistant
AML [7].
Umbilical cord blood (CB) is rich in hematopoietic
stem cells, and has become an alternative source for
stem cell transplantation for hematologicmalignancies
[8,9]. As a stem cell source for transplant it offers sev-
eral advantages over unrelated marrow or blood stem
cells such as ease of availability, tolerance to greater
HLA mismatch, and potentially lower incidence of
GVHD. Yet its success is limited by cell dose and
lack of donor lymphocyte infusions to eliminate post-
transplant residual disease or treat relapse. Several ap-
proaches are under investigation to improve the CB
transplant outcome, including coinfusion of multiple
units, ex vivo expansion of CB stem cells, reduced in-
tensity conditioning (RIC), and development of adop-
tive immunotherapies [9,10].
Adult NK cells are derived from CD341/HLA-
DR1 human progenitor cells, which differentiate
into NK progenitors. Certain cytokines provide a syn-
ergistic culture environment for the differentiation of
NK progenitor cells such as FLT-3L, IL-3, and IL-
15 [11-13]. Committed immature NK cells progres-
sively acquire CD56 and CD16 expression as well as
killer cell immunoglobulin-like receptors (KIRs), nat-
ural cytotoxicity receptors (NCRs), and CD94-NKG2
receptors. CB contains a higher percentage ofNK pro-
genitor cells than adult blood, which can mature into
NK cells with significant cytotoxicity [14-16].
Mesenchymal stem cells (MSC) can be obtained
from various tissue sources, and are capable of differ-
entiating into tissues of mesenchymal and endodermal
origin as well as support hematopoiesis and inhibit T
cell proliferation [17]. The umbilical cord contains
a jelly-like matrix (Wharton’s Jelly), rich in pluripotent
mesenchymal stem cells (UC-MSC), which has been
recently characterized as a novel source of MSC
[18-22]. These cells produce significant amounts of
cytokines, and we hypothesized that a feeder layer of
irradiated UC-MSC would effectively support ex vivo
expansion of CB-NK cells through cytokine stimula-
tion. The objective of this study was to determine
whether an UC-MSC-based expansion system for
CD3-depleted CB-MNC (CD3dep CB-MNC) cells
could lead to clinically relevant numbers of NK cells
that can be considered for cellular immunotherapy.
We sought to optimize expansion conditions including
use of different cytokine combinations and source of
feeder cells (from same or allogeneic cords), and con-
tact versus no contact with UC-MSC feeder cells.Our results show that the feeder layer system results
in a .60-fold expansion of NK cells, which remain
functional and could be considered for cell therapies.
MATERIALS AND METHODS
Collection and Preparation of CB and UC-MSC
CB samples and umbilical cords were obtained
from normal full-term vaginal or Caesarian deliveries
after informed consent. The study was approved by
the institutional review board of Tufts Medical Center
(Boston, MA). The umbilical cord was rinsed with PBS
and cut into small pieces (0.5-1 cm) and placed into
6-well plates. UC-MSCwere isolated as described pre-
viously [19] and expanded in culture flasks with 20%
FBS/RPMI 1640 (Cambrex, Walkersville, MD) sup-
plemented with antibiotics (Penicillin 100 IU/mL,
Streptomycin 100 mg/mL, Amphotericin B 0.25 mg/
mL fromGibco Invitrogen (Carlsbad, CA), andCipro-
floxacin 10 mg/mL from Mediatech (Herndon, VA).
CB was collected in citrate phosphate dextrose
(CPD) sterile blood-pack unit (Baxter, Deerfield, IL)
and processed within 24 hours after delivery. CB-
MNC were isolated by density gradient centrifugation
using Ficoll-Hypaque Plus (Amersham Biosciences,
Piscataway, NJ) and depleted of CD31 lymphocytes
by immunomagnetic bead selection using the Midi-
MACS system (Miltenyi Biotec, Auburn, CA) accord-
ing to the manufacturer’s instructions. The final elute,
designated here as CD3dep CB-MNC, was used to ini-
tiate NK expansion and consistently contained\1%
CD31 cells. Cells were either freshly cultured or
cryopreserved with 10% DMSO in FBS at 280C
and thawed.
NK Expansion Cultures
UC-MSC (1  104 cells/well) were plated in 24-
well plates with 20% FBS/RPMI 1640 overnight,
gamma-irradiated with 3500 cGy, and incubated for
2-4 hours before being used as a feeder layer. CD3dep
CB-MNCwere plated with or without the feeder layer
of UC-MSC either from the same (autologous) or
from an unrelated (allogeneic) cord donor, with or
without different combinations of the following cyto-
kines: IL-2 (1000 IU/mL; Chiron, Emeryville, CA),
IL-15 (10 ng/mL), IL-3 (10 ng/mL), and FLT-3L
(10 ng/mL; R&D Systems, Minneapolis, MN). To de-
termine optimum condition, expansions were per-
formed with different CD3dep CB-MNC:UC-MSC
ratios. To determine whether contact between UC-
MSC and CD3dep CB-MNC cells was necessary, ex-
pansions with direct feeder contact at 1:1 ratio were
compared with those where cells were separated by
a 1.0-mmpore PETmembrane cell culture insert (Bec-
ton Dickinson, Franklin Lakes, NJ). Cells were har-
vested at an average of 16 6 2 days, counted with
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NK expansion was calculated as follows.
Foldexpansion5 [(final expandedMNCnumber)
(final % of CD561/CD32)]/[(initial MNC number) 
(initial % of CD561/CD32)].
Cell Lines
Human leukemia cell lines K562 (CML in blast
crisis), Raji (human Burkitt’s lymphoma), REH, and
SUP-B15 (both acute B-precursor ALL), were ob-
tained from American Type Culture Collection
(ATCC, Rockville, MD). These cell lines were main-
tained in suspension cultures using 20% FBS/RPMI
1640 as described above.
Phenotyping of Surface Antigens, and Flow
Cytometry
Phycoerythrin (PE)-conjugated anti-CD56, allo-
phycocyanin (APC)-conjugated anti-CD117, fluores-
cein isothiocyanate (FITC)-conjugated anti-CD3,
anti-CD19, and anti-CD14 were obtained from BD
Pharmingen (San Diego, CA). APC-conjugated anti-
bodies against CD16, CD158a (KIR2DL1/DS1),
CD158e (KIR3DL1), CD158i (KIR2DS4), CD335
(NKp46), CD336 (NKp44), CD337 (NKp30), and
CD314 (NKG2D) were obtained from Miltenyi Bio-
tech (Auburn, CA). The expression of these markers
on CD3dep CB-MNC before and after expansions
was analyzed by flow cytometry on a CyanTM flow cy-
tometer (Dako, Carpinteria, CA) using Summit v4.3
software.
Cytotoxicity Assay
Cytotoxic activity of NK cells from fresh, over-
night IL-2 activated, or 2 weeks expanded CD3dep
CB-MNC was determined by a flow cytometry-based
assay [23]. Briefly, target cells were prestained with the
green fluorescent membrane dye PKH67-GL (Sigma-
Aldrich, St. Louis, MO), and effector cells were mixed
with target cells in 96-well V-bottom plates at various
effector-to-target (E:T) ratios, in 20% FBS/RPMI
1640. After incubation at 37C for 4 hours, the cell
mixtures were centrifuged at 1700 rpm for 5 minutes
and stained with Propidium Iodide (PI), 10 mg/mL
(Sigma-Aldrich). Dead target cells were identified as
PKH67-GL and PI double positives. Target cells
and effector cells were also stained separately with PI
to assess spontaneous cell lysis. Percentage of target
cell killing was calculated as follow:
% Killing 5 (% total target lysis) 2 (% spontane-
ous target lysis).
The NK to target ratios were calclated using the
actual number of CD561/CD32 NK cells within the
CD3dep CB-MNC population used as an effector.Transfection of Expanded NK Cells with Reporter
Genes
Fresh or expanded CD3dep CB-MNC were trans-
fected by electroporation with plasmid pCMV-GFP
(gift from Dr. Lidija Covic, Tufts Medical Center,
Boston, MA), or with GFP mRNA obtained by in vitro
transcription (T7 mMessage mMachine kit, Ambion
Applied Biosystems, Austin, TX) of a pXT7-GFP tem-
plate plasmid (gift from Pr. Sergei Sokol, Mount Sinai
School ofMedicine,NewYork), according to theman-
ufacturer’s instructions. Two different electroporation
methodswere tested:Genepulser II electroporator (Bi-
orad, Hercules, CA) using different conditions of volt-
age and capacitance, and theNucleofactor transfection
system (Amaxa Biosystems, Cologne, Germany) using
a human NK cell Nucleofactor Kit (Amaxa) according
to the manufacturer’s instructions. GFP fluorescence
and PI staining in the CD561/CD32 NK population
were determined 24 hours after electroporation using
flow cytometry.
Statistical Analysis
Data are presented asmean6 SEMvalues. For sta-
tistical analysis, Student’s t-test was used. Groups
compared were considered to be significantly different
if P\ .05.
RESULTS
UC-MSC Support NK Cell Expansion
Fresh CD3dep CB-MNC cocultured with
UC-MSC for 2 weeks, at a CD3dep CB-MNC to
a UC-MSC ratio of 10:1 (with all 4 cytokines) showed
an expansion of 12.86 3.0-fold in total MNC number.
Culture with cytokines in the absence of UC-MSC re-
sulted in MNC expansion of 4.16 0.8-fold (P5 .024),
and cocultured with UC-MSC without cytokines did
not support any MNC expansion at all (0.2 6 0.1-
fold, P 5 .004) (Table 1). Cocultures using different
CD3dep CB-MNC toUC-MSC ratios showed inferior
expansion (data not shown). In cocultures with
UC-MSC and cytokines the proportion of CD561/
CD32 cells increased from 9.2 6 1.4% in fresh
CD3dep CB-MNC to 48.6 6 2.7% after 2 weeks,
which corresponded to a 64.7 6 8.4-fold expansion
of NK cells. NK expansion in culture with UC-MSC
feeder layer only or with cytokines only was 0.1 6
0.1-fold and 6.4 6 1.5-fold, respectively (Figure 1A).
No CD31 or CD191 cells were detected after 2 weeks
under any of these conditions. Expansion of frozen and
thawed CD3dep CB-MNC samples under the same
culture conditions was poor (6.5 6 3.2-fold increase
of NK) and inconsistent, with high variability between
cord samples. In contrast, using fresh or cryopreserved
UC-MSC from autologous or allogeneic sources as
a feeder layer did not show any difference with respect
to their ability to support NK cells expansion (data not
1034 L. Boissel et al.Table 1. CD3 Depleted CB-MNC Expansion in the Presence of Different Combinations of Cytokines, with or without a Feeder Layer of UC-MSC, at
a CD3dep CB-MNC:UC-MSC Ratio of 10:1
Categories Mean Fold MNC Expansion P Initial NK% Final NK% n
All CYTw/UC-MSC 12.8 ± 3.0 — 9.2 ± 1.4 48.6 ± 2.7 8
IL-21FLT-3L w/UC-MSC 3.5 ± 0.7 0.017 10.8 ± 2.2 48.7 ± 2.5 4
IL-21IL-15 w/UC-MSC 2.1 ± 0.3 0.009 10.8 ± 2.0 48.5 ± 12.4 4
IL-21IL-3 w/UC-MSC 11.6 ± 4.9 0.831 10.8 ± 2.0 26.7 ± 6.4 5
IL-2 w/UC-MSC 1.9 ± 0.3 0.009 10.8 ± 2.0 63.4 ± 5.7 5
All CYTw/o UC-MSC 4.1 ± 0.8 0.024 9.2 ± 1.4 13.8 ± 2.3 8
No CYTw/UC-MSC 0.2 ± 0.1 0.004 10.8 ± 2.0 2.7 ± 1.1 5
No CYTw/o UC-MSC 0.1 ± 0.1 0.004 10.8 ± 2.0 2.5 ± 2.2 5
NKpercentage was determined by the proportion of CD561/CD32 cells in the population, P values were calculated compared with all cytokines
w/UC-MSC.shown). Therefore, only data obtained with fresh
CD3dep CB-MNC and allogeneic UC-MSC are
reported here. Of note is the observation that the
UC-MSC feeder layer started to disappear within
the first week of culture, with no UC-MSC left after
the 2-week culture period.
Figure 1.Optimization ofNK cell expansion. (A) Comparison of ex-
pansion of NK cells with or without a UC-MSC feeder layer
(CD3dep CB-MNC:UC-MSC ratio of 10:1) and in the presence of
different cytokine combinations (all CYT 5 IL-2, IL-3, IL-15,
and FLT-3L). Expansions are reported as fold increases in
CD561/CD32 NK cells. (B) Comparison of expansion of NK cells
with or without contact with a UC-MSC feeder layer. Cultures
were performed in 6-well plates at a CD3dep CB-MNC:UC-MSC
ratio of 1:1, in the presence of all 4 cytokines or IL-2 alone. Controls
were without UC-MSC feeder layer.Cytokine and Contact Requirements for Optimum
NK Expansion
The combination of 4 cytokines (IL-2, IL-3, IL-
15, FLT-3L) was compared to IL-2 alone and 2 cyto-
kine combinations described below, all expanded on
a feeder layer of irradiated UC-MSC. Mean fold NK
expansion with the 4-cytokine combination (see above)
was significantly greater than with IL-2 alone (12.2 6
2.0), IL-21 FLT-3L (14.46 2.4), IL-21 IL-15 (10.4
6 4.1), or IL-2 1 IL-3 (25.2 6 8.1) (Figure 1A). IL-2
alone promoted higher NK percentage in the cultured
population (63.4 6 5.7%) but did not promote signif-
icant MNC proliferation. In contrast, combination of
IL-2 and IL-3 promoted MNC proliferation to
a similar extent as the combination of 4 cytokines but
favored cell types other than NK (26.7 6 6.4%)
(Table 1).
Expansion of NK cells was significantly greater
when CD3dep CB-MNC cells were directly plated
onto irradiated UC-MSC cells (a ratio of 1:1) com-
pared to cell insert cultures where the feeder layer
was placed at the bottom of the plates and CD3dep
CB-MNC cells were seeded on the cell insert mem-
brane (Figure 1B). In the presence of the combinations
of 4 cytokines (IL-2, FLT-3L, IL-15, and IL-3), mean
fold NK expansion at 2 weeks was 31.36 3.3 with con-
tact and 15.0 6 4.2 without contact.
Surface Antigen Expression of Fresh and Expanded
NK Cells
NK cells were analyzed by flow cytometry using 3-
color staining for expression of CD16, CD117,
KIR2DL1/DS1, KIR3DL1, KIR2DS4, NKp46,
NKp44, NKp30, and NKG2D within the
CD561CD32 NK cells population, before and after
2 weeks expansion, with and without UC-MSC feeder
cells (Figure 2). Intermediate and late NK precursors
have been recently characterized as CD561/CD32/
CD1171 cells [24]. Fresh CD3dep CB-MNC con-
tained 3.3 6 0.7% of these precursors, whereas
CD3dep CB-MNC expanded with or without UC-MSC
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respectively.
The initial proportion of CD56bright cells within
the NK population was 6.9 6 1.4% in fresh CD3dep
CB-MNC and significantly increased to 76.8 6 9.4%
and 71.5 6 7.5% in CD3dep CB-MNC expanded
with or without UC-MSC feeder, respectively.
Although NK cells from fresh CD3dep CB-MNC
expressed some CD16 (28.4 6 8.3%), expanded NK
cells did not express CD16. The percentage of NK
cells expressing NKp46, NKp30, and NKG2D did
not change significantly before and after 2 weeks in
culture, with or without feeder (Figure 2B). Con-
versely, expression of NKp44 was greatly increased af-
ter expansion (93.06 2.6% and 92.86 1.0% with and
without MSC, respectively, compared to 5.5 6 2.8%
initially, P 5 .0001).
Cytotoxicity of Fresh, Activated, and ExpandedNK
Cells
Fresh CD3dep CB-MNC were tested for NK cells
cytotoxic activity against K562, Raji, REH, and SUP-
B15 cell lines. Nonactivated CD3dep CB-MNC cells
did not efficiently lyse any of these targets
(Figure 3A). However, overnight incubation in IL-2
Figure 2. Comparison of expression of NK receptors before and af-
ter expansion (A, B). Percentages of CD161, CD1171, KIR2DL1/
DS11, KIR3DL11, KIR2DS41, NKp461, NKp441, NKp301,
and NKG2D1 among CD561/CD32 cells were determined before
(gray) and after expansion, with a feeder layer (white) at a CD3dep
CB-MNC:UC-MSC ratio of 10:1 or without a feeder layer (black).(1000 U/mL) resulted in a significant increase in cyto-
toxicity against all 4 cell lines (Figure 3B). CD3dep CB-
MNC cells expanded on UC-MSC feeders showed
strong killing of K562 but consistently lower killing
of REH, Raji, and SUP-B15 than observed for CD3dep
CB-MNC cells after overnight incubation in IL-2
(Figure 3C). CD3dep CB-MNC cells expanded with-
out UC-MSC feeders (cytokines only) showed very
limited cytotoxic activity against K562 and none
against the other cell lines (Figure 3D).
Transfection of Expanded NK cells with Reporter
Genes
One of the major thrusts in cellular therapies is to
be able to engineer cells such that they can be targeted
to specific tumor antigens. To test transfection effi-
ciency of NK cells, we used plasmid GFP DNA and
mRNA with different transfection protocols and con-
ditions. As summarized in Table 2, transfection effi-
ciency of NK cells from fresh or expanded CD3dep
CB-MNC using a Biorad electroporator with a variety
of different conditions was no more than 4.5% for
GFP DNA (up to 10% for GFP mRNA). The Nucle-
ofactor system from Amaxa, that provides an NK
cell-customized transfection medium, also gave poor
transfection yields for GFP DNA (9.0 6 2%) but sig-
nificantly better transfection for GFP mRNA (52 6
18%). However, reproducibility of the transfection
was inconsistent, and cell mortality caused by both
transfection protocols was significant (74.0 6 12.5%
for Amaxa, 90.0 6 7% for Biorad).
DISCUSSION
In this study, we aimed to define and optimize con-
ditions for ex vivo expansion of NK cells from CB,
which are potential tools for adoptive immunotherapy.
NK cells are emerging as an alternative to T cells, par-
ticularly because they can be given across MHC bar-
riers [2,4-6]. Because lymphocyte infusion from the
original stem cell donor is not an option for CB trans-
plant recipients and the number of NK cells is limited
in a given CB unit, we developed a method that allows
to expand NK cells and progenitors to cell numbers
that could be sufficient to treat patients posttransplant.
Beyond the treatment for patients after transplant, ex-
panded NK cells could also be administered to cancer
patients, and could potentially be more therapeutically
efficacious if they are engineered to be targeted to in-
dividual cancers, that is, by introducing a chimeric an-
tigen receptor (CAR) recognizing tumor antigens
[23,25-27]. Earlier studies had already shown that
CB contains a fair number of NK cell progenitors
that can be identified by expression of surface antigens
CD34 andHLA-DR and that combination of the cyto-
kines FLT-3L, IL-2, IL-3, and IL-15 results in some
expansion of CB progenitor cells in culture [11-13].
1036 L. Boissel et al.Figure 3. Comparison of the cytotoxic properties of fresh, activated, and expanded NK cells. CD3dep CB-MNC were tested for NK cells cyto-
toxicity against K562 (black square), Raji (black diamond), REH (white square), and SUP-B15 (white triangle) either on the same day (A), after
overnight incubation with IL-2 (1000 IU/mL) (B), and after expansion with (C) or without (D) a UC-MSC feeder layer in the presence of all 4
cytokines. The indicated ratios represent effector (5CD561/CD32 NK) to target.Similarly, use of irradiated lymphocytes or EBV trans-
fected B cells as feeder layers can result in augmented
expansion, which likely occurs through production of
lymphokines by the feeder cells [28]. However, this ap-
proach is not suitable for clinical applications, as un-
wanted cells remain in the ‘‘gemisch’’ that potentially
can cause GVHD or infections.
We pursued here a different approach to augment
expansion of NK cells using a feeder layer of allogeneic
irradiated MSC derived from the Wharton’s jelly of
the umbilical cord. To prevent a GVHD reaction in
recipients of an allogeneic NK cell product or over-
growth of T cells in the expansion cultures, CD31
lymphocytes were removed from CB-MNC by immu-
nomagnetic separation. The remaining cells (CD3dep
CB-MNC) were then placed on the UC-MSC feedersupplemented with the combination of cytokines men-
tioned before. Under these conditions we were able to
obtain on average 65-fold expansion of NK cells after 2
weeks in culture and without T cell contamination. It
is quite possible that some of the cells that remain after
CD3 depletion of CB-MNC (such as monocytes) actu-
ally contribute to the expansion of NK cells. This as-
sumption is supported by observations by Gada et al.
[29] that highly enriched CD561 cells from CB-
MNC showed inferior ex vivo expansion (only 4.5-
fold) compared to CB-MNC that were CD3-depleted
only (14-fold). Both cell fractions were cultured with
IL-2 and IL-15 for 2 weeks.
Of clinical relevance is our observation that frozen
CD3dep CB-MNC cells inconsistently expanded, and
if so, generally at a much lower frequency. ActivatedTable 2. Comparison of Viability and Expression of GFP in Expanded NK cells When Using Different Conditions of Electroporation and Different Vectors
Nucleic Acid Type Device Conditions % GFP Range (%) % PI1 Range (%)
cDNA Amaxa Prg U-01 9.3 ± 1.9 7 to 13 73.5 ± 12.5 61 to 86
mRNA Amaxa Prg U-01 52.5 ± 18.4 0 to 80 74.0 ± 12.5 50 to 92
cDNA Biorad 300V 150 mF 4.5 ± 4.5 0 to 9 N/A /
cDNA Biorad 400V 400 mF 2.0 N/A N/A /
mRNA Biorad 250V 300 mF 0.3 ± 0.3 0 to 0.5 90.0 ± 7.0 83 to 97
mRNA Biorad 300V 150 mF 10.0 ± 10.0 0 to 30 89.5 ± 5.3 83 to 96
mRNA Biorad 300V 300 mF 0.4 ± 0.4 0 to 0.8 89.5 ± 7.5 82 to 97
GFP % in the table was determined in the viable (PI negative) cell population.
N/A 5 not available.
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when using standard cryopreservation conditions [30],
and it is conceivable thatNKprogenitor cells in CB are
variably sensitive to cryopreservation.
Our data using cell culture inserts, that separate
CD3dep CB-MNC cells from UC-MSC, suggest that
contact between these 2 cell populations is advanta-
geous for optimized expansion of NK cells. At this
time it remains speculative which surface molecules
on UC-MSC are responsible for this effect. Of note
is that even without contact there was better expansion
of NK cells in cultures that contained UC-MSC than
in cultures that did not contain any feeder layer. This
indicates that UC-MSC produce molecules/cytokines
that are supportive of NK progenitor cell expansion.
MSC produce a host of cytokines, and it appears that
the cytokine profile of ‘‘earlier’’ MSC (such as UC-
MSC) is different from that of bone marrow derived
MSC [19].
Because MSC do not produce IL-2 or IL-15, these
cytokines remain essential for any ex vivo culture unless
the MSC are genetically engineered to produce those
cytokines. We have shown before that UC-MSC can
easily be transfected [19], and hence, lend themselves
to serve as customized feeders for a number of different
human cells for expansion. First data indicate that
other cells may be multifold expanded with modified
MSC as feeders [31].
We observed the disappearance of UC-MSC dur-
ing the 2-week culture time. It is possible that the ini-
tial irradiation of the UC-MSC did not support their
survival for that length of time. Alternatively, the NK
cells, because of the allogeneic reactivity between
NK cells and UC-MSC, could lyse the MSC over
time. We observed the disappearance of the layer usu-
ally after the first week. This observation is similar to
that of Spaggiari et al. [32], who have described the
lysis of allogeneic MSC by activated NK cells.
The expression of inhibitory NK receptors did not
change significantly after coculture expansion. Expres-
sion of activating receptors by NK cells was also un-
changed except for the acquisition of the activating
receptor NKp44, which is usually expressed on cyto-
kine-activated NK cells. The percentage of CD561/
CD1171 cells increased significantly (P5 .0216), sug-
gesting that our culture conditions supported expan-
sion of NK precursors. Of note is that the expanded
NK cells consisted mostly of CD56bright/CD16-
cells. This subpopulation is known to predominantly
produce cytokines and to be less cytolytic than
CD56dim/CD161 cells. This could explain why we ob-
served less killing of REH, Raji, and SUP-B15 target
cells by expanded NK cells compared to just over-
night-activated NK cells. Of note also is that NK cells
from fresh, nonactivated CD3dep CB-MNC or from
CD3dep CB-MNC expanded without feeder layer dis-
play negligible cytotoxicity.Our long-term goal is to makeNK cells targeted to
cancer surface antigens through transfection with
CARs [23,26,27]. To decrease risks for the recipient
and minimize the regulatory requirements, we sought
to achieve this objective through the use of nonviral
vectors and electroporation. Previous work from our
group had shown that the NK-92 cell line could be
transfected with CAR with high efficiency using either
a DNA vector or mRNA [27].We therefore attempted
to transfect NK cells with DNA plasmid or mRNA
constructs for GFP. Although we used 2 different
methods of transfection (electroporation and nucleo-
fection), the transfection efficiency for NK cells, either
activated overnight or expanded for 2 weeks, was con-
sistently low, with the majority of cells dying off. Our
results suggest that genetic manipulation of NK cells
from CB is feasible, but that other likely vector con-
structs such as lentiviruses may be preferable for trans-
fection [33]. In summary, we present here a method for
optimized expansion of functionalNK progenitor cells
fromCB after CD3 depletion by using a feeder layer of
UC-MSC. Further studies will be directed to engineer
UC-MSC to circumvent the need for exogenous cyto-
kines and to improve the retargeting of NK cells.
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